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ABSTRACT
Background:  Guidelines from 2005 for treating suspected sepsis in low- and middle-income 
countries (LMIC) recommended hospitalisation and prophylactic intramuscular (IM) or 
intravenous (IV) ampicillin and gentamicin. In 2015, recommendations when referral to hospital 
is not possible suggest the administration of IM gentamicin and oral amoxicillin. In an era of 
increasing antimicrobial resistance, an updated review of the appropriate empirical therapy for 
treating sepsis (taking into account susceptibility patterns, cost and risk of adverse events) in 
neonates and children is necessary.
Methods:  Systematic literature review and international guidelines were used to identify 
published evidence regarding the treatment of (suspected) sepsis.
Results: Five adequately designed and powered studies comparing antibiotic treatments in a 
low-risk community in neonates and young infants in LMIC were identified. These addressed 
potential simplifications of the current WHO treatment of reference for infants for whom 
admission to inpatient care was not possible. Research is lacking regarding the treatment 
of suspected sepsis in neonates and children with hospital-acquired sepsis, despite rising 
antimicrobial resistance rates worldwide.
Conclusions:  Current WHO guidelines supporting the use of gentamicin and penicillin for 
hospital-based patients or gentamicin (IM) and amoxicillin (oral) when referral to a hospital is not 
possible are in accordance with currently available evidence and other international guidelines, 
and there is no strong evidence to change this. The benefit of a cephalosporin alone or in 
combination as a second-line therapy in regions with known high rates of non-susceptibility is 
not well established. Further research into hospital-acquired sepsis in neonates and children is 
required.
Introduction
Sepsis remains a leading cause of mortality and mor-
bidity, especially during the first five days of life and in 
low- and middle-income countries (LMIC) [1]. In 2015, 
of the 5.9 million deaths of children under the age of 
5 years, 45% were of neonates, and this figure exceeded 
50% in several regions [2]. Neonatal sepsis is the third 
most common cause of death in this age group with an 
estimated 0.4 million deaths in 2015, the vast majority 
of which were in LMIC [3]. Beyond the neonatal period, 
the first year of life carries the highest risk of death from 
sepsis.
In high-income countries (HIC), early-onset neonatal 
sepsis (EONS) is defined by occurring in the first 72 h after 
birth, as opposed to late-onset neonatal sepsis (LONS, 
onset  ≥  72  h after birth). In LMIC, many neonates are 
born outside health care facilities, and might become 
infected with community-acquired pathogens even after 
72 h of life. As a result, neonatal sepsis in LMIC is often 
classified as community- and hospital-acquired instead 
of early- and late-onset [4].
WHO provides guidelines for the management of 
common childhood illnesses, through the Pocket Book 
of Hospital Care for Children published for the first 
time in 2005 [5]. The second edition was published in 
2013 [6]. It is one of a series of documents and tools 
supporting the Integrated Management of Childhood 
Illness (IMCI). These guidelines focus on management 
of the major causes of childhood mortality in coun-
tries with limited health care (and other) resources. 
Recommendations for preventing neonatal infection 
and for the management of possible serious bacterial 
infection remain the same in the second edition. It rec-
ommends providing prophylactic intramuscular (IM) 
or intravenous (IV) ampicillin and gentamicin in neo-
nates with documented risk factors for infection for at 
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Against this background, concerns are increasing regard-
ing bacterial pathogens with reduced susceptibility to 
empirical medication with variations both between and 
within LMIC [9].
The potential need to revise the existing WHO guide-
lines based on new antimicrobial resistance (AMR) data 
or evidence relating to drug safety in neonates and chil-
dren must be evaluated. This review collates evidence to 
support current empirical antibiotic recommendations 
for suspected or confirmed sepsis in neonates and chil-
dren according to the most recent (≥year 2012) relevant 
studies.
Methods
An iterative systematic literature search was undertaken 
to identify published clinical evidence relevant to the 
review question. Searches were conducted in MEDLINE 
and Embase. Databases were searched using relevant 
medical subject headings, free-text terms and study-
type filters, where appropriate. Search terms included 
variations of ‘anti-bacterial agents’, ‘antibiotic’, ‘sepsis’ and 
‘bacteraemia’. Limits were set for the appropriate popu-
lation, i.e. ‘all child (0 to 18 years)’. Studies published in 
languages other than English were not reviewed. The 
search was undertaken for manuscripts published from 
2012 to cover the most recent WHO guidelines (WHO 
Pocket Book of Hospital Care for Children, 2013).
Potentially relevant studies were identified from 
the search results by reviewing titles and abstracts. 
Full papers were then obtained and reviewed against 
pre-specified inclusion (antimicrobial choice, compar-
isons between different antibiotics and/or antibiotic 
classes and/or comparisons with placebo, drug thera-
peutic use, drug efficacy, drug safety and harm, drug 
resistance) and exclusion criteria (only bacterial sepsis 
was considered, case reports were not considered) to 
least 2 days and then to reassess. Treatment should be 
continued only if there are signs of sepsis (or positive 
blood culture). It recommends hospitalisation and IM or 
IV antibiotic therapy with a combination of gentamicin 
and benzylpenicillin or ampicillin for at least 7–10 days 
in infants aged <2 months who fulfil the case definition 
of serious bacterial infection. If infants are deemed to 
be at risk of staphylococcal infection, IV cloxacillin and 
gentamicin are recommended.
In many LMIC, these parenteral treatments might 
only be available where inpatient neonatal and pae-
diatric care can be provided, and access to these treat-
ments is limited by transportation, financial and/or 
cultural factors. In previous studies, even when these 
constraints were addressed, a substantial proportion 
of families still refused referral to hospital for young 
infants with possible serious bacterial infection (PSBI). 
A body of research undertaken in the past decade led 
to the development and publication in 2015 of the 
first guideline for Managing Possible Serious Bacterial 
Infection in Young Infants When Referral is not Possible 
[7] in infants aged <59 days. The guideline recommends 
(Table 1):
Option 1: IM gentamicin 5–7.5  mg/kg (for low-birth-
weight infants gentamicin 3–4  mg/kg) once daily for 
7  days and twice daily oral amoxicillin, 50  mg/kg per 
dose for 7 days.
Option 2: IM gentamicin 5–7.5  mg/kg (for low-birth-
weight infants gentamicin 3–4  mg/kg) once daily for 
2  days and twice daily oral amoxicillin, 50  mg/kg per 
dose for 7 days.
Thus, penicillin/gentamicin is recommended for 
community neonatal sepsis, hospital neonatal sepsis 
and all sepsis in children. It is known, however, that in 
many countries, agents with a broader spectrum such 
as third-generation cephalosporins (e.g. ceftriaxone) are 
commonly used to treat neonatal and infant sepsis [8]. 
Table 1.  current Who recommendation for antibiotic therapy in infants aged 0–59  days with signs of possible serious bacterial 
infection or for prophylaxis.
Reference Conditions Antibiotics Dosing regimen
Pocket Book of hospital 
care for children, 
2013
Prophylaxis in neonates with 
documented risk factors
iM or iV ampicillin and  gentamicin 
for at least 2 days
Gentamicin (iM/iV):
First week of life
low-birthweight infants: 3 mg/kg once a day; normal 
birthweight: 5 mg/kg per dose once a day
Weeks 2–4 of life: 7.5 mg/kg once a day
Ampicillin (iM/iV):
First week of life: 50 mg/kg every 12 h
Weeks 2–4 of life: 50 mg/kg every 8 h
Benzylpenicillin (penicillin G) (iM):
First week of life: 50,000 U/kg every 12 h; weeks 2–4 and 
older: 50,000 U/kg every 6 h
Procaine benzylpenicillin (iM):
50,000 U/kg once a day
Cloxacillin (iV):
First week of life: 25–50 mg/kg every 12 h
Weeks 2–4 of life: 25–50 mg/kg every 8 h
case definition PsBi iM or iV gentamicin and 
 benzylpenicillin or ampicillin for 
at least 7–10 days
Greater risk of staphylococcus 
infection
iV cloxacillin and gentamicin for at 
least 7–10 days
Managing possible  
serious bacterial  
infection in young 
infants when referral 
is not possible, 2015
referral to hospital for young 
infants with PsBi is not 
possible
option 1: iM gentamicin once  
daily for 7 days and oral 
 amoxicillin twice daily for 7 days 
Gentamicin: iM 5–7.5 mg/kg (for low-birthweight infants 
gentamicin 3–4 mg/kg) once daily
Amoxicillin: oral 50 mg/kg twice daily
option 2: iM gentamicin once  daily 
for 2 days and oral  amoxicillin 
twice daily for 7 days 
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identify studies that addressed the review question. 
Fungal and viral sepsis were not taken into account in 
this review, although invasive candidiasis is an important 
emerging cause of LONS.
The Cochrane Database for Systematic Reviews was 
also searched using the terms ‘sepsis’ AND ‘antibiotic’.
Five international guidelines were reviewed: the 
Surviving Sepsis Campaign endorsed by the Infectious 
Diseases Society of America (IDSA) [10], the National 
Institute for Health and Care Excellence (NICE) [11,12], 
the American Academy of Pediatrics (AAP) [13–15], 
the British Medical Journal (BMJ) Clinical Evidence 
[16] and the British National Formulary for Children 
(BNFc) [17].
Results
Evidence for current WHO recommendations: penicillin 
and gentamicin in community-based neonatal sepsis
A randomised controlled trial (RCT) undertaken in three 
low-income communities in Pakistan evaluated the fail-
ure rates of three clinic-based antibiotic regimens in 
young infants with clinical signs of PSBI (≤59 days old, 
n  =  434) whose families refused hospital referral [18]. 
Infants were randomly allocated to receive: (i) procaine 
penicillin and gentamicin, reference arm, (ii) ceftriax-
one or (iii) oral trimethoprim–sulfamethoxazole and 
gentamicin for 7  days. Results showed that the effi-
cacy of a procaine benzylpenicillin–gentamicin com-
bination was much higher than that of trimethoprim/
sulfamethoxazole–gentamicin [treatment failure was 
significantly higher with trimethoprim/sulfamethoxaz-
ole–gentamicin compared with penicillin–gentamicin 
(relative risk 2.03, 95% confidence interval 1.09–3.79)]. 
Differences were not significant in the ceftriaxone versus 
penicillin–gentamicin comparison (relative risk 1.69, 95% 
CI 0.89 to 3.23).
The two SATTs (Simplified Antibiotic Therapy Trial) 
were large RCTs, one of which was conducted in five 
centres in Bangladesh (four urban hospitals and one 
urban field) [19] and the other in five centres in Pakistan 
[20]. It included young infants (≤59 days old, n = 2367 
and ≤ 59 days old, n = 2251 per protocol, respectively) 
for whom referral to hospital was not possible. The 
trial compared the standard treatment of injecta-
ble procaine benzylpenicillin–gentamicin for 7  days 
(group A) with two alternative regimens: (i) injectable 
gentamicin and oral amoxicillin for 7 days (group B), 
and (ii) intramuscular procaine benzylpenicillin and 
gentamicin for 2 days, then oral amoxicillin for 5 days 
(group C). The results suggested that the two alterna-
tive regimens were as efficacious as the standard regi-
men when hospital admission was refused. In the SATT 
trial in Bangladesh, treatment failed in 78 (10%) infants 
in group A compared with 65 (8%) infants in group B 
and 64 (8%) in group C. The risk difference between 
groups B and A was −1.5% (95% CI −4.3 to 1.3) and 
between groups C and A was −1.7% (95% CI −4.5 to 
1.1). Non-fatal severe adverse events were rare. Three 
infants in group A, two in group B and three in group C 
had severe diarrhoea [19]. In the SATT trial in Pakistan, 
treatment failed within 7 days of enrolment in 90 (12%) 
of infants in group A compared with 76 (10%) infants 
in group B and 99 (13%) in group C. The risk difference 
between groups B and A was −1.9% (95% CI −5.1 to 
1.3) and between groups C and A was −1.7% (−2.3 to 
4.5) [20].
One of two large RCTs from the AFRINEST (AFRIcan 
NEonatal Sepsis Trial) Group compared oral amoxicil-
lin with injectable procaine benzylpenicillin plus gen-
tamicin in five African centres in young infants (≤59 days 
old, n = 2333) with fast breathing as a single sign of PSBI 
illness when referral was not possible. In the procaine 
benzylpenicillin–gentamicin group, 234 infants (22%) 
failed treatment compared with 221 (19%) infants in 
the oral amoxicillin group (risk difference 2.6%, 95% 
CI −6.0 to 0.8). The results were taken to indicate that 
young infants with fast breathing alone can be effec-
tively treated with oral amoxicillin as outpatients when 
referral to hospital is not possible [21].
The second large RCT from the AFRINEST Group, 
undertaken in the same countries, compared the cur-
rent reference treatment for PSBI of injectable procaine 
benzylpenicillin–gentamicin for 7 days (group A) with 
a simplified regimen in young infants (≤59  days old, 
n  =  3564) when referral was not possible. The follow-
ing simplified regimens were investigated: (i) injectable 
gentamicin and oral amoxicillin for 7  days (group B), 
(ii) injectable procaine benzylpenicillin–gentamicin for 
2 days, then oral amoxicillin for 5 days (group C), (iii) or 
injectable gentamicin for 2 days and oral amoxicillin for 
7 days (group D) [22]. Treatment failed in 67 (8%) infants 
in group A compared with 51 (6%) in group B (risk dif-
ference −1.9%, 95% CI −4.4 to 0.1), 65 (8%) in group C 
(risk difference −0.6%, 95% CI −3.1 to 2.0) and 46 (5%) in 
group D (risk difference −2.7%, 95% CI −5.1 to 0.3). The 
results suggest that the three simplified regimens were 
as effective as injectable procaine benzylpenicillin–gen-
tamicin for 7 days on an outpatient basis in young infants 
with clinical signs of severe infection, without signs of 
critical illness, and whose caregivers could not accept 
referral for hospital admission.
In these five aforementioned studies [18–22], the 
equivalence margin was predefined at 5%. Based on 
in vitro data from LMIC on a benzylpenicillin and gen-
tamicin regimen (~4000 blood culture isolates) [23], a 
significant proportion of bacteraemia is not covered: 
43% in neonates and 37% in infants of 1–12  months. 
However, this was not confirmed by the SATT trial in 
Pakistan which, of the five aforementioned studies, is the 
only one which obtained blood cultures in the majority 
of patients (84%) [20]. Thirty-two (86%) of 37 pathogens 
tested for antimicrobial susceptibility were sensitive to 
amoxicillin and gentamicin [20]. Interestingly, of the 
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2067 blood cultures obtained, only 81 (4%) were posi-
tive for a micro-organism. Overall, mortality was low in 
the SATT and AFRINEST studies: it was 2% in each group 
comparing the reference treatment of injectable pro-
caine benzylpenicillin–gentamicin for 7 days with two 
alternative regimens [19], <1% in each group compar-
ing amoxicillin with benzylpenicillin–gentamicin [20,21] 
and ≤2% in each group comparing the reference treat-
ment of injectable procaine benzylpenicillin–gentamicin 
for 7 days with the three simplified dosing regimens [22].
Drug management in hospital-based neonatal sepsis
Two other studies in the Asian region were found. One, 
a retrospective study in hospitalised neonates and chil-
dren (≤59 months of age, n = 183) in Bangladesh, inves-
tigated injected ampicillin and gentamicin as a first-line 
combination for the management of sepsis [24]. Another 
single-centre prospective study in India of hospitalised 
neonates (≤59 months old, n = 90) compared two empir-
ical regimens: a cloxacillin and amikacin combination 
(n = 40) versus a cefotaxime and gentamicin combina-
tion (n = 50) for at least 10 days in cases of late-onset sep-
sis [25]. The study analyses of these reports are unclear 
and either they do not address the stated primary out-
come (mortality between the two groups) or specify the 
statistical methods used for analyses, or do not provide 
numerical values for non-significant results [24,25].
All other studies retrieved since 2012 which compared 
the impact of different antibiotic regimens and/or routes 
of administration on outcome were undertaken in hospi-
talised patients in HIC, mainly in North America. Because 
of the considerable differences in pathogen spectrum, 
resistance patterns, but also levels and types of underly-
ing diseases, it is unlikely that the results of these studies 
are directly generalisable to LMIC [26,27].
Third-generation cephalosporin monotherapy versus 
in combination with another antibiotic
Historically, combination therapy has been used to 
increase coverage and because of its potential additive 
clinical effect. While studies tend to show that there is 
no difference in clinical outcomes or mortality between 
mono- and combined therapy, increased toxicities with 
combination therapy has been documented [28,29].
Four studies since 2012 were found which compared 
β-lactam monotherapy with β-lactam combined with 
aminoglycoside in hospitalised paediatric patients in 
the USA [27,29–31].
In the retrospective studies by Berkowitz et al. [30] 
(n = 203) and Tama [29] (n = 879), there was no differ-
ence in 30-day mortality between the β-lactam mono-
therapy and the combination therapy of aminoglycoside 
and β-lactams for Gram-negative bacteria in children. 
Combination therapy consisting of a β-lactam agent and 
an aminoglycoside was not superior to monotherapy 
with a β-lactam agent alone for managing enterobacte-
riaceae bacteraemia in children. But patients receiving 
combination therapy had approximately twice the risk 
of nephrotoxicity compared with those receiving mono-
therapy (odds ratio 2.15, 95% CI 2.09 to 2.21) [29].
In a study of neonates and young infants (≤59 days 
old, n = 265), based on in vitro susceptibilities from iso-
lates, third-generation cephalosporins combined with 
ampicillin would have been effective for 98.5% of infants 
but unnecessarily broad with a third-generation cepha-
losporin use for 83.8% of infants with suspected serious 
bacterial infection [27]. Because of the 20 Enterococcus 
faecalis isolates (7.5% of identified pathogens), intrinsi-
cally resistant to cephalosporins, third-generation ceph-
alosporin monotherapy was less effective than either 
combination (p < 0.001).
In a retrospective study in which children receiving 
empirical combination therapy were matched 1:1 with 
children receiving empirical monotherapy [31], the 
10-day mortality was similar in children (aged > 2 months 
to 14  years, n  =  452) receiving empirical combination 
therapy versus empirical monotherapy (odds ratio 0.84, 
95% CI 0.28 to 1.71). A survival benefit was observed 
when empirical combination therapy was prescribed 
for children growing multidrug-resistant Gram-negative 
organisms (n = 46) in the bloodstream (odds ratio 0.70, 
95% CI 0.51 to 0.84).
A systematic review in 2013 assessed β-lactam mon-
otherapy versus β-lactam-aminoglycoside combination 
therapy in patients with sepsis. It included 69 randomised 
and quasi-randomised trials but only four included chil-
dren. In trials comparing the same β-lactam, there was no 
difference between study groups with regard to all-cause 
mortality (Relative Risk RR 0.97, 95% CI 0.73 to 1.30) and 
clinical failure ((RR) 1.11, 95% CI 0.95 to 1.29). In studies 
comparing different β-lactams, a trend for benefit with 
monotherapy for all-cause mortality (RR 0.85, 95% CI 0.71 
to 1.01) and a significant advantage for clinical failure (RR 
0.75, 95% CI 0.67 to 0.84) was observed, but the studies 
included were generally classified as being of low quality. 
No significant disparities emerged from analyses of par-
ticipants with Gram-negative infection. Nephrotoxicity 
was significantly less frequent with monotherapy (RR 
0.30, 95% CI 0.23 to 0.39) [28].
Evidence for alternative antibiotic treatment options
One RCT conducted in India compared amikacin mon-
otherapy with piperacillin/tazobactam monotherapy as 
empirical treatment for suspected EONS (n = 187) [32]. In 
this neonatal unit, amikacin or piperacillin–tazobactam 
was the standard regimen since reported resistance rates 
previously ranged between 86% and 89% for ampicillin, 
gentamicin and cefotaxime. Treatment failure defined 
as a blood culture isolate resistant to the allocated 
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antibiotic or as a change of antibiotic was very low (n = 3 
and n = 2, respectively, p = 0.44). No increased risk or 
significant difference between the two study groups in 
the incidence of secondary infection within 7  days of 
stopping the study antibiotic was observed, nor any dif-
ference in the incidence of fungal sepsis, nor a difference 
in all-cause mortality at days 7 and 28. However, only five 
blood cultures were positive.
A retrospective single-centre study in neonates 
(5–37 days old, n = 10) with persistent CoNS bacteraemia 
(LONS) investigated the addition of rifampicin to vanco-
mycin for infection resolution [33]. Bacteraemia persisted 
for a median of 9 days (range 6–19) until the initiation 
of rifampicin. In all cases, the bacteraemia resolved with 
vancomycin–rifampicin without serious side effects and 
in all patients the blood cultures became negative on 
vancomycin–rifampicin taken 24–72 h after the initiation 
of rifampicin. No serious side effects were observed.
Synopsis of international guidelines
Table 2 summarises recommendations by international 
organisations. When selecting empirical treatment regi-
mens, most guidelines suggest relying on data on antibi-
otic resistance patterns in locally prevalent pathogens at 
the institutional level but do not define how this should 
be done. They recommend individualising empirical 
antibiotic recommendations according to local antibiotic 
protocols and local pathogen susceptibility. There is little 
if any detail on how such data are to be used to select 
treatment regimens. For EONS, most guidelines are in 
line with WHO recommendations: NICE, AAP, BMJ and 
BNFc recommend the use of benzylpenicillin or ampi-
cillin combined with gentamicin as empirical treatment 
and list third-generation cephalosporins as an alterna-
tive. Of note, guidelines often state that the aim is to 
target the most common pathogens in EONS, i.e. group 
B streptococcus (GBS) and Escherichia coli in HIC. More 
variability is seen in the suggested empirical treatment 
for LONS.
Dosing consideration
International guidelines differ on dosing regimens for 
gentamicin, from 4 to 5 mg/kg every 24–36 h. Current 
WHO guidelines recommend a once-daily dosing reg-
imen, from 3 to 7.5  mg/kg/day according to age and 
birthweight.
Gentamicin has a narrow therapeutic index. Efficacy 
of aminoglycosides has been associated with high peak 
concentrations relative to minimum inhibitory concen-
tration (MIC) of the infecting micro-organism with a ratio 
peak concentration/MIC of >8–10, whereas low trough 
concentrations appear to be associated with reduced risk 
of nephro- and ototoxicity (at least <2 mg/L, but <1 mg/L 
is also often advocated) [34,35].
Although the incidence of ototoxicity detected fol-
lowing aminoglycoside exposure remains low (1–3%) 
and less than that reported in adults, gentamicin appears 
to be the least cochleotoxic. The specific association 
between hearing loss and aminoglycoside exposure 
is complicated, mainly owing to the presence of many 
other confounding factors in this population, e.g. low 
gestational age and birthweight, intrauterine and post-
natal infections, neonatal asphyxia, requirement for 
prolonged oxygen therapy and respiratory support, 
congenital malformations, family history of hearing 
impairment, genetic abnormalities [36]. An association 
with high peak concentration has been suggested in the 
past but recent studies are not so categorical [35,36].
A recent systematic review considered the risk of gen-
tamicin toxicity in neonates treated for PBSI in LMIC with 
the WHO recommended first-line antibiotics (gentamicin 
with penicillin) [37]:
•  Six trials reported formal assessments of ototoxic-
ity outcomes in neonates treated with gentamicin, 
and the pooled estimate for hearing loss was 3% 
(95% CI 0 to 7%).
•  Nephrotoxicity was assessed in 10 studies but 
could not be evaluated owing to variation in the 
case definitions used.
•  Estimates of the number of neonates potentially 
affected by gentamicin toxicity were not under-
taken owing to insufficient data.
The authors concluded that data were insufficient to 
assess the potential for harm in terms of toxicity associ-
ated with gentamicin treatment.
The volume of distribution of gentamicin is larger in 
preterm neonates as a consequence of a higher percent-
age of body water compared with term neonates. Kidney 
function is reduced in preterm neonates owing to incom-
plete nephrogenesis. As a consequence, recent trends 
are in favour of higher doses (>4 mg/kg up to 5 mg/kg) 
with extended dose intervals in preterm neonates (>24 h 
up to 48 h for the most preterm infants or more accord-
ing to some authors) [38–42] to achieve higher peak con-
centrations for improved efficacy while maintaining low 
trough concentrations for safety. According to currently 
available knowledge, term infants should receive about 
4.0–4.5 mg/kg every 24 h [43–45].
However, rates of multidrug-resistant Gram-negative 
(MRD GN) infections are increasing worldwide, particu-
larly in LMIC. As a result, many enterobacteraciae gen-
tamicin MIC are 4 or higher nowadays, compared with 
0.5 or 1 in the past when dosing recommendations were 
developed, and so determining the appropriate dosing 
recommendations has become very challenging. It might 
be possible that even higher doses are required to reach 
effective exposure (10× MIC) with longer extended dos-
ing interval periods (to prevent toxicity). Such question-
ing emphasises the urgent need for further prospective 
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Table 2. current international guidelines for the empirical treatment of suspected sepsis or blood infection.
Guideline Last update Recommendations 
surviving sepsis 
campaign(endorsed 
by idsa)
2012 •  administration of effective intravenous antimicrobials within the first hour of recognition of septic 
shock (grade 1B) and severe sepsis without septic shock (grade 1c) is the goal of therapy
•  Initial empiric anti-infective therapy of one or more drugs which have activity against all likely 
pathogens (bacterial and/or fungal or viral) and penetrate in adequate concentrations into tissues 
presumed to be the source of sepsis (grade 1B)
•  Combination empirical therapy for neutropenic patients with severe sepsis (grade 2B) and for 
patients with difficult-to-treat, multidrug-resistant bacterial pathogens such as acinetobacter 
and pseudomonas spp. (grade 2B). For patients with severe infections associated with respiratory 
failure and septic shock, combination therapy with an extended spectrum beta-lactam and either 
an aminoglycoside or a fluoroquinolone is recommended for P. aeruginosa bacteremia (grade 2B). a 
combination of beta-lactam and macrolide for patients with septic shock from bacteraemic Strepto-
coccus pneumoniae infections (grade 2B) is recommended
•  empirical combination therapy should not be administered for more than 3–5 days (grade 2B)
•  duration of therapy typically 7–10 days; longer courses may be appropriate in patients with a slow 
clinical response, undrainable foci of infection and bacteremia with S. aureus; also some fungal and 
viral infections or immunologic deficiencies, including neutropenia (grade 2c)
•  Special pediatric consideration:
•  the empiric drug choice should be changed as epidemic and endemic ecologies dictate (grade 1d)
•  Clindamycin and anti-toxin therapies for toxic shock syndromes with refractory hypotension (grade 
2d)
•  Clostridium difficile colitis should be treated with enteral antibiotics if tolerated. Oral vancomycin is 
preferred for severe disease (grade 1a)
nice 2016 •  neonates presenting in hospital with suspected sepsis in their first 72 h: iV benzylpenicillin 25 mg/
kg twice daily (increase to 3 times daily if clinically concerned) and gentamicin (starting dose 5 mg/
kg every 36 h). Minimum 7-day course of iV antibiotics for strong suspicion of sepsis or a positive 
blood culture
•  neonates, community-acquired sepsis:
•  >40 weeks corrected gestational aGe: ceftriaxone 50 mg/kg once daily unless already receiving an 
intravenous calcium infusion at the time
•   ≤ 40 weeks corrected gestational age or receiving an intravenous calcium infusion: cefotaxime 
50 mg/kg every 6–12 h, depending on the age of the neonate
•  Up to 17 years, community acquired sepsis: ceftriaxone 80 mg/kg once a day with a maximum dose 
of 4 g daily at any age
•  Up to 17 years, hospital acquired sepsis or patients who are known to have previously been 
infected with or colonised with ceftriaxone-resistant bacteria: consult local guidelines for choice of 
antibiotic
•  For children younger than 3 months, give an additional antibiotic active against listeria (for exam-
ple, ampicillin or amoxicillin)
aaP 2012, 2015 •  early-onset sepsis:
•  Broadspectrum antimicrobial agents [ampicillin 150 mg/kg per dose intravenously (iV) every 12 h 
and an aminoglycoside (usually gentamicin 4 mg/kg per dose iV every 24 h)]. once a pathogen is 
identified, antimicrobial therapy should be narrowed (unless synergism is needed)
•  third-generation cephalosporins (e.g. cefotaxime) represent a reasonable alternative to an amino-
glycoside. Bacteraemia without an identifiable focus of infection is generally treated for 10 days
notes: 
•  antimicrobial therapy should be discontinued at 48 h in clinical situations in which the probability 
of sepsis is low (controversial)
•  risk of resistance to cefotaxime. owing to excellent csF penetration, suggest to restrict to infants 
with meningitis attributable to Gram-negative organisms
•  to cover group B streptococcus (GBs) and Escherichia coli
•  late-onset sepsis admitted from the community: ampicillin 75 mg/kg per dose iV every 6 h and 
gentamicin 4 mg/kg per dose iV every 24 h
•  late-onset sepsis, hospitalised since birth: vancomycin: 10 to 20 mg/kg every 12 to 48 h according 
serum creatinine level and gentamicin 4 mg/kg per dose iV every 24 h
BMJ clinical evidence 2016 treatment should be initiated with broad-spectrum antibiotic cover appropriate for the prevalent 
organisms for each age group and geographical area. this should be changed to an appropriate 
narrow-spectrum antibiotic regimen once a causative pathogen is identified
•  early-onset sepsis: cited as example: benzylpenicillin plus gentamicin (from nice guidelines) or 
ampicillin plus gentamicin or cefotaxime
note: to cover group GBs and Gram-negative bacilli
late-onset sepsis: (selective therapy for empirical antibiotics regimen):
•  Cited as an example: ampicillin plus gentamicin or cefotaxime, or vancomycin plus gentamicin or 
cefotaxime
•  Ceftazidime or piperacillin/tazobactam may be added to the empirical regimen if Pseudomonas is 
suspected
•  Metronidazole or clindamycin may be added to the empirical regimen to cover for anaerobes/ne-
crotising enterocolitis
•  infants and young infants, community-acquired infection:
•  Third-generation cephalosporin (e.g. cefotaxime, ceftriaxone)
•  infants and young infants, hospital-acquired infection:
•  Extended-spectrum penicillin (e.g. piperacillin/tazobactam) or carbapenem (e.g. meropenem)
•  additional broadening of this cover (e.g. with gentamicin, ciprofloxacin, or vancomycin) may be 
considered depending on case-specific factors. Clindamycin should be used for toxin-induced toxic 
shock syndromes with refractory hypotension
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studies in populations with MRD GN specifically collect-
ing PBSI isolates (there are few isolates to date) with MICs 
to gentamicin, actual dosing and peak concentration/
trough estimation, and both clinical outcomes (infection 
resolution, toxicity).
Using the 24-h dosing interval for all neonates 
suggested by WHO may expose a large proportion of 
patients to the risk of toxicity, especially when treatment 
is prolonged (>48 h), because of the possibility of drug 
accumulation. However, providing various dosing inter-
vals that stratify neonates may complicate feasibility and 
acceptability.
Pharmacokinetics data for neonates are scarce and 
so it is difficult to summarise current dosing regimens 
note: idsa – infectious diseases society of america.
Guideline Last update Recommendations 
BnFc 2015/16 •  septicaemia in neonates ≤72 h old:
•  Benzylpenicillin sodium, 50 mg/kg in neonate under 7 days every 12 h, in neonate 7–28 days every 
8 h
•  and
•  Gentamicin 5 mg/kg in neonates up to 6 days every 36 h; in neonates 7–28 days: every 24 h
•  if Gram-negative septicaemia suspected: add cefotaxime iM or iV 25 mg/kg in neonates under 
7 days every 12 h, in neonates 7–21 days every 8 h; neonates 21–28 days every 6–8 h; dose is 
doubled in severe infection and meningitis
and stop benzylpenicillin sodium if Gram-negative infection confirmed
•  septicaemia in neonates >72 h old:
•  Flucloxacillin, oral 25 mg/kg in neonate under 6 days twice daily; neonates 7–20 days 3 times daily; 
neonates 21–28 days 4 times daily; iV 25 mg/kg in neonates under 6 days every 12 h; in neonates 
7–20 days every 8 h; in neonates 21–28 days every 6 h; may be doubled in severe infection
•  and
•  Gentamicin (see dose above)
•  or Amoxicillin iV 50 mg/kg in neonates under 7 days every 12 h; in neonates 7–28 days every 8 h,
•  or Ampicillin iV 50 mg/kg in neonates up to 6 days every 12 h; in neonates 7–20 days every 8 h; in 
neonates 21–28 days every 6 h
•  and
•  Cefotaxime (see dose above)
•  For 7 days
•  child 1 month – 18 years, community-acquired sepsis:
•  aminoglycoside, e.g. gentamicin initially 7 mg/kg, then adjusted according to serum gentamicin 
concentration or multiple daily dose regimen with child aged 1 month–12 years: 2.5 mg/kg every 
8 h; child 12–18 years 2 mg/kg every 8 h
•  and
•  Amoxicillin 50 mg/kg every 4–6 h (max. 2 g every 4 h)
•  or Ampicillin 50 mg/kg every 4–6 h (max. per dose 2 g every 4 h)
•  or Cefotaxime alone 50 mg/kg every 8–12 h; increase to every 6 h in very severe infections and 
meningitis (max. 12 g daily) or ceftriaxone alone iM or iV 1 g daily, increased to 2–4 g daily, 
increased dose to be used in severe infections
•  if pseudomonas or resistant micro-organism suspected: broad-spectrum anti-pseudomonal 
beta-lactam [piperacillin–tazobactam: 90 mg/kg (max. 4.5 g) every 6 h]
•  if anaerobic infection suspected, add metronidazole, oral in child 1–2 months 7.5 mg/kg every 
12 h; in child 2 months–12 years 7.5 mg/kg (max. 400 mg) every 8 h; in child 12–18 years 
400 mg every 8 h; rectal in child 1 month–1 year 125 mg 3 times daily for 3 days, then twice daily 
thereafter; in child 1–5 years 250 mg 3 times daily for 3 days, then twice daily thereafter; in child 
5–10 years 500 mg 3 times daily for 3 days then twice daily thereafter; in child 10–18 years 1 g 
3 times daily for 3 days then twice daily thereafter; iV in child 1–2 months 15 mg/kg as a single 
loading dose followed after 8 h by 7.5 mg/kg every 8 h; in child 2 months–18 years 7.5 mg/kg 
(max. 500 mg) every 8 h
•  if Gram-positive infection suspected, add glucloxacillin oral in child 1 month–1 year 62.5–125 mg 
4 times daily; in child 2–9 years 125–250 mg 4 times daily; in child 10–17 years 250–500 mg 4 
times daily; iM in child 1 month–18 years 12.5–25 mg/kg every 6 h (max. 500 mg every 6 h); iV in 
child 1 month–18 years 12.5–25 mg/kg every 6 h (max. 1 g every 6 h); may be doubled in severe 
infection
•  or Vancomycin 15 mg every 8 h (max. 2 g per day)
•  or Teicoplanin initially 10 mg/kg every 12 h (max. 400 mg per dose) for 3 doses, then (by iV infu-
sion or iM injection) 6 mg/kg once daily (max. 400 mg per dose); (after initial 3 doses subsequent 
doses can be given by iM route, if necessary, although, iV is preferable). For severe infection: 
initially 10 mg/kg every 12 h for 3 doses, 10 mg/kg once daily for 5 days
•  child 1 month–18 years, hospital-acquired sepsis:
•  Broadspectrum anti-pseudomonal beta-lactam: piperacillin-tazobactam 90 mg/kg (max. 4.5 g) 
every 6 h or ticarcillin/clavulanic acid, child under 40 kg: 80 mg/kg every 8 h (increased if neces-
sary to 80 mg/kg every 6 h, increased frequency used for more severe infections); child ≥40 kg: 
3.2 g every 6–8 h (increased if necessary to 3.2 g every 4 h, increased frequency for more severe 
infections)
•  or Imipenem/cilastatin, in child 1–2 months iV 20 mg/kg every 6 h; in child 3 months–17 years iV 
15 mg/kg every 6 h (max. 500 mg per dose) (life-threatening infection: 25 mg/kg every 6 h, max. 
1 g per dose)
•  or meropenem, in child 1 month–11 years (bodyweight ≥50 kg) 2 g every 8 h; in child 12–17 years 
2 g every 8 h
•  if pseudomonas or resistant micro-organism suspected add aminoglycoside (see dose above)
•  if Mrsa suspected add vancomycin or teicoplanin (see dose above)
•  if anaerobic infection suspected add metronidazole (see dose above) to a broadspectrum cepha-
losporin (see dose above for cefotaxime and ceftriaxone) for 5 days
Table 2. (Continued).
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of β-lactams in this review. Antibacterial activity of 
β-lactams is best characterised by time-dependent kill-
ing. The pharmacokinetic-pharmacodynamic parame-
ter that correlates with the clinical and bacteriological 
efficacy of β-lactam antibiotics is the percentage of 
time that the serum free drug concentration exceeds 
the MIC for the pathogen (time above the MIC). Overall, 
β-lactams present a favourable safety profile and most 
dosing recommendation suggested by WHO are in line 
with current knowledge [45].
Review of harm and toxicity – safety
Safety and harm toxicity data for empirical antibi-
otic treatment used in PSBI are summarised in Table 3 
[37,46–55].
Pathogen distribution and antimicrobial resistance 
patterns
Pathogen distribution. In HIC, the most common 
causes of EONS are GBS and E. coli. The remaining 
cases of EONS are caused by Staphylococcus aureus, 
coagulase-negative staphylococci (CoNS), Listeria 
monocytogenes and other Gram-negative bacteria [4]. 
In LONS (mainly in very low-birthweight infants), the 
main pathogens are CoNS, responsible for half of the 
episodes. Other important aetiological agents are E. 
coli, klebsiella spp. and candida spp. Less common 
causes of LONS include S. aureus, enterococcus spp. and 
Pseudomonas aeruginosa [4,56].
Aetiological data from LMIC, particularly from rural, 
community-based studies, are very limited. In systematic 
reviews on this topic, the commonest causes of neonatal 
bacteraemia in LMIC are S. aureus, E. coli and klebsiella 
spp. and, in older infants, S. aureus, Streptococcus pneu-
moniae, klebsiella spp. and E. coli, and non-typhoidal 
salmonella [23,57]. Although there are some similari-
ties between community- and hospital-acquired sepsis, 
available data are of insufficient quality to justify firm 
conclusions [4]. Acinetobacter spp., for example, appear 
to be predominant in some regions [58,59], while the 
incidence is very low in other regions. GBS is responsible 
for only 2–8% of cases in LMIC. It is possible that infants 
with GBS infection are underreported, since this patho-
gen usually presents very early in life and infected new-
borns might die or be adequately treated before blood 
cultures or other relevant microbiological samples are 
obtained. CoNS is responsible for a lower proportion 
of hospital-acquired infections than in HIC [4], and this 
may be related to the use of invasive medical devices, 
e.g. central venous catheters. Interestingly, in the SATT 
Table 3. safety data summary for empirical antibiotic treatment used in possible serious bacterial infection.
Antibiotic Adverse events and contraindications Relevant interactions
natural penicillin:
Benzylpenicillin sodium
aminopenicillin:
Ampicillin
Amoxicillin
antistaphylococcal penicillin:
Cloxacillin
serious toxicity is rare in association with penicillin therapy
•  diarrhoea is the most common
•  incidence is increased following use of amoxicillin/clavulanate (broad-
spectrum therapy) compared with the use of amoxicillin
•  there is some evidence that different ratios of the amoxicillin to 
clavulanic acid components may affect the proportion of children who 
experience diarrhoea
•  the incidence of diarrhoea following amoxicillin use was significantly 
lower for b.i.d. than with t.i.d. regimen (6.7–9.6 vs. 10.3–26.7%, respec-
tively) in one study
•  drug-induced rash, hypersensitivity, anaphylaxis
•  Penicillin allergy has been estimated to affect 1–10% of people given 
penicillins. true incidence of penicillin allergy in patients who report 
that they are allergic is actually <10%
•  Very rarely, seizures
•  important consideration if higher than usual doses or dose frequencies, 
or following rapid administration of high intravenous doses (therefore 
should be infused over at least 30 min)
•  electrolyte imbalances (e.g. sodium salts)
•  hepatotoxicity, mild/moderate gastro-intestinal effects
concomitant use of bacteriostatic antibac-
terial agents (i.e. tetracyclines, sulfona-
mides, erythromycins, chloramphenicol) 
should be avoided
caution should also be exerted with the 
use of certain other β-lactam antibiot-
ics, namely cephalosporins (especially 
1st- and 2nd-generation, e.g. cefalex-
in, cefaclor) and carbapenems (e.g. 
meropenem) as cross-reactivity in the 
allergies between these classes can occur 
(but its importance has frequently been 
overstated)
3rd-generation cephalosporin: 
Cefotaxime
•  Mainly hypersensitivity and gastro-intestinal effects (mostly diarrhoea)
•  •rarely causes nephrotoxicity or seizures in neonates
concurrent use of cephalosporin with:
•  nephrotoxic drugs (aminoglycosides) 
increased risk of nephrotoxicity
•  Warfarin may result in an increased risk 
of bleeding
3rd-generation cephalosporin: 
Ceftriaxone
•  Mainly hypersensitivity and gastro-intestinal effects (mostly diarrhoea)
•  hyperbilirubinemia (ability of ceftriaxone to displace bilirubin from 
serum albumin binding sites)
•  cholestasis and pseudolithiasis owing to biliary sludging (with high 
concentration of ceftriaxone in the system)
•  concomitant administration of intravenous ceftriaxone and calci-
um-containing solutions is not recommended since concurrent ad-
ministration with calcium-containing solutions may produce insoluble 
precipitates (ceftriaxone-calcium salts) leading to cardiorespiratory 
complications
concurrent use of cephalosporin with:
•  nephrotoxic drugs (aminoglycosides) 
increased risk of nephrotoxicity
•  Warfarin may result in an increased risk 
of bleeding
Broadspectrum antibiotics 
and prolonged duration of 
antibiotic therapy
•  increased risk of invasive candidiasis and death
•  increased risks of necrotising enterocolitis (nec), death and late-onset 
sepsis
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in Pakistan which obtained blood cultures from 2067 
(84%) infants, a high frequency of campylobacter was 
found in the absence of diarrhoea (22% of the positive 
blood cultures) [20].
Regarding local variations, Figures 1 (neonates) and 
2 (children) show the pathogen distribution for studies 
conducted in specific LMIC reported after 2005. These 
data demonstrate the heterogeneity likely to be encoun-
tered in settings for which the WHO essential medicines 
list is relevant. In particular, it is not presently possible 
to definitively delineate the specific role played by bac-
teria which are difficult to treat, e.g. Klebsiella spp. and 
Acinetobacter spp. The relative incidence of these path-
ogens may have a considerable impact on the probable 
cover by different empirical regimens as certain bac-
teria are intrinsically resistant or display high levels of 
acquired resistance to commonly used antibiotics, which 
lowers their coverage.
Antimicrobial resistance patterns
Only very limited reliable data on antimicrobial suscepti-
bility are available from Asia, Latin America and Africa. It 
is evident from existing summaries of the data that there 
is considerable antibiotic resistance to many commonly 
used antibiotics with variations both between and within 
regions in LMIC [57,60].
According to a systematic review and meta-anal-
ysis by Downie et al. [23], more than 40% of cases of 
community-acquired neonatal bacteraemia in LMIC are 
resistant or have reduced susceptibility to a combina-
tion of penicillin and gentamicin and to third-generation 
cephalosporins, thus suggesting that third-generation 
cephalosporins are no more effective in treating sep-
sis than the currently recommended antibiotics, ben-
zylpenicillin and gentamicin. More than 35% of cases 
of community-acquired bacteraemia in infants aged 
Figure 1. Pathogen distribution for studies conducted in a specific setting and reported after 2005 in neonates.
notes: staaur, S. aureus; stacoa, coagulase-negative staphylococci; strepspp, streptococci; straga, S. agalactiae; entcocspp, enterococci; other Gpos, other 
Gram-positive pathogens; esccol, E. coli; klespp, klebsiella spp; psespp, pseudomonas spp; entbacspp, enterobacter spp; acispp, acinetobacter spp., other 
Gneg: other Gram-negative pathogens.
Figure 2. Pathogen distribution for studies conducted in a specific setting and reported after 2005 in children.
notes: staaur, S. aureus; stacoa, coagulase-negative staphylococci; strpne, S. pneumonia; strepspp, streptococci; strpyo, S. pyogenes; entcocspp, enterococci; 
other Gpos, other Gram-positive pathogens; esccol, E. coli; klespp, klebsiella spp; psespp, pseudomonas spp; entbacspp, enterobacter spp; acispp, 
acinetobacter spp; salspp, salmonella spp; other Gneg, other Gram-negative pathogens.
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1–12 months are resistant or have reduced susceptibility 
to the combination of penicillin and gentamicin and to 
third-generation cephalosporins. In neonates, the gaps 
in antibiotic coverage with either benzylpenicillin/ampi-
cillin and gentamicin or third-generation cephalospor-
ins regimens were mostly in infections owing to enteric 
Gram-negative bacilli, particularly klebsiella spp. [23]. 
However, in the Pakistan SATT trial, it was reassuring that 
the majority of micro-organisms tested (32/37) were sus-
ceptible to gentamicin and amoxicillin [20].
Similar findings were reported in a 2015 systematic 
review of studies which estimated AMR rates in Gram-
negative bloodstream infections in children in LMIC 
[58]. Gram-negative bacteria accounted for 67% of all 
episodes. The predominance of klebsiella spp. with 
a high prevalence of resistance to gentamicin in Asia 
(69%, Interquartile Range (IQR) 19–95%) and Africa (54%, 
IQR 0–68%) and the overall level of resistance of Gram-
negative bacteria to third-generation cephalosporins 
(Asia 84%, IQR 45–95%; Africa 50%, IQR 0–87%) were 
very concerning.
All reviews published to date note the very low num-
ber of studies with adequate data. In particular, many of 
the studies reviewed had a high risk of bias with substan-
tial uncertainty about how representative the data are for 
each setting. There are concerns that the data published 
are mainly from larger tertiary neonatal units, many of 
which might have higher rates of resistance owing to 
a nosocomial outbreak. In addition, virtually no clinical 
outcome data are reported (a finding confirmed by this 
review), particularly relating to the underlying disease, 
pathogen phenotype, empirical antibiotic treatment 
and clinical outcome. This imposes major limitations to 
selecting empirical regimens on the basis of their clinical 
impact.
Discussion
Since 2012, only suspected community neonatal sepsis 
has been addressed and there have been no adequate 
studies in other settings. Five adequately designed 
and powered studies which compared antibiotic treat-
ments in a low-risk community setting in neonates and 
young infants (0–59 days) in LMICs were found [18–22]. 
They addressed potential simplifications of the current 
WHO treatment of reference, particularly for infants for 
whom admission to inpatient care was not acceptable 
or possible. In this group of infants, evidence suggests 
that treatment regimens could potentially be simplified, 
for example, by using injectable gentamicin for 2 days 
and oral amoxicillin for 7 days for young infants [22]. We 
hypothesise that the regimen of injectable gentamicin 
for 2  days and oral amoxicillin for 7  days would offer 
advantages over others investigated by requiring fewer 
invasive procedures with only two injections, promoting 
treatment adherence, and by allowing administration of 
high doses of aminoglycoside to target high MIC, while 
preventing drug accumulation over days and thus poten-
tial toxicity (mostly nephrotoxicity) based on a once-daily 
dosing regimen. However, these studies did not evaluate 
regimens and/or agents outside of those currently on 
the essential medicines list. Also, they were limited to a 
specific subpopulation of infants and children (≤59 days 
old, weight ≥ 1500 g) with suspected sepsis. Enrolment 
according to the diagnosis of PSBI was based on the 
presence of any sign of clinical severe infection except 
signs of critical illness (unconsciousness and convulsions) 
[19–22]. As it was a community-based, low-risk study, 
a considerable proportion of treated infants might not 
have had a bacterial infection. Indeed, in the single trial 
that performed blood cultures (Pakistan SATT trial), only 
4% were positive for a pathogen [20]. It is also unclear 
what the rates of antimicrobial resistance were in these 
settings, but sensitivities to the aminoglycoside-based 
regimens are likely to be higher than in facility-based 
settings, and the results of susceptibility testing in the 
Pakistan SATT trial tend to confirm this, although the 
number of samples tested (37) was very low. In the 
Pakistan SATT, the presence of bacteraemia did not pre-
dict treatment failure in per-protocol infants [10 (13%) 
of 75 children with bacteraemia and 227 (12%) of 1618 
without bacteraemia had treatment failure (risk differ-
ence 1.03, 95% CI −6.8 to 8.9)]. Overall, studies assess-
ing the efficacy of specific antibiotic regimens in infants 
and children with blood culture-proven sepsis and/or the 
effectiveness of different regimens in infants and chil-
dren with nosocomial sepsis are virtually lacking. Given 
the challenges of increasing levels of antibiotic resistance 
in LMIC (based on evaluation of blood cultures usually 
collected from inpatients or at least on presentation at 
hospital) and the considerable variation in the patterns 
of bacteria causing bacteraemia, for example, with the 
predominance of klebsiella spp. and acinetobacter spp., 
it might be expected that additional antibiotic options 
will be required. Closing the existing gaps in evidence 
must be made a priority so that any additions/changes 
to the recommended regimens are based on robust data. 
All the other trials addressing antibiotic regimens in neo-
natal and paediatric sepsis that were identified were 
disappointing in terms of design (often retrospective), 
power (low sample size) and outcomes (not performed in 
LMIC, method not always well-reported, drug dose often 
not reported). In addition, it is essential to have more 
data on causative pathogens and their susceptibilities 
in order to understand which treatment regimens could 
be effective and should be prioritised for further inves-
tigation. There are virtually no relevant studies with rig-
orous methods to direct therapeutic options in children. 
Fundamental concepts of effective antimicrobial therapy 
in critically ill children (proper culture techniques, timely 
initiation of therapy, selection of agents with a high 
likelihood of susceptibility and sufficient penetration 
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to the site of infection, adequate doses and intervals 
to enhance bactericidal activity) are often impractical 
in LMIC owing to limited resources and infrastructure. 
Overall, a recommendation to amend the current WHO 
antibiotic regimens for PSBI cannot be made.
The utility of third-generation cephalosporins as sec-
ond-line treatment is under debate based on the sparse 
microbiological surveillance data available. Additionally, 
there is major concern about the widespread use of 
third-generation cephalosporins and selection for 
multidrug Gram-negative infections in neonatal units. 
Further efforts are urgently needed to investigate alter-
native older off-patent therapeutic antimicrobials such 
as colistin, polymixin B or fosfomycin, to delineate their 
efficacy and safety in the paediatric population and to 
determine their potential contribution to antimicrobial 
regimens in LMIC settings.
In conclusion, current WHO guidelines which support 
the use of gentamicin and penicillin for inpatients or gen-
tamicin (IM) and amoxicillin (IM, per os) when admission 
is not possible accord with currently available evidence 
and other international guidelines, and there is no strong 
evidence to change this guidance. The absence of almost 
any adequate evidence to suggest revision of the guid-
ance for sepsis in hospital setting for neonates or any 
setting for children is a major concern.
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